Objective: This study aims to investigate the clinical application value of high-frequency ultrasound technology in diagnosing subcutaneous lipohypertrophy at insulin injection sites in diabetes patients.
Methods: All diabetes patients treated in our hospital from January 2022 to January 2023 were selected as the study subjects. The incidence of subcutaneous lipohypertrophy was calculated at the end of the study period. All patients were screened, and those meeting the inclusion criteria were registered, and basic data were collected. Patients were screened for subcutaneous lipohypertrophy using conventional clinical examination (control group) and high-frequency ultrasound technology (study group).
Results: The study found that the incidence of subcutaneous lipohypertrophy in diabetes patients receiving insulin injections in our hospital from January 2022 to January 2023 was 80.99%. The average longitudinal diameter of subcutaneous lipohypertrophy in these patients was 11.66 (7.56, 21.44) mm, the transverse diameter was 12.04 (8.96, 18.29) mm, depth was (5.62±2.17) mm, and the area was 188.79 (76.85, 331.78) mm². The clinical detection rate in the study group was higher than that in the control group (P<0.05). The quantity of detected sites was greater in the study group compared to the control group (P<0.05).
Conclusion: The incidence of subcutaneous lipohypertrophy in diabetes patients receiving insulin injections is relatively high clinically, and high-frequency ultrasound technology demonstrates significant potential in diagnosis. By providing high-resolution imaging and quantitative data, it effectively improves the clinical detection rate and clarifies symptoms. This technology is likely to become an important auxiliary tool in future diabetes treatment, providing more precise treatment plans for patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10961026 | PMC |
| http://dx.doi.org/10.2147/DMSO.S443737 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cutaneous Adverse Effects From Diabetes Devices in Pediatric Patients With Type 1 Diabetes Mellitus: Systematic Review.
JMIR Dermatol
November 2024
Rowan-Virtua School of Osteopathic Medicine, 113 Laurel Rd, Stratford, NJ, 08084, United States, 1 (856) 566-6789.
Article Synopsis
- Continuous glucose monitoring (CGM) and continuous subcutaneous insulin infusions (CSII) are essential treatments for type 1 diabetes (T1D), but they may cause dermatologic complications like contact dermatitis and lipodystrophies, which negatively affect glycemic control and patient adherence.
- A systematic review analyzed 30 studies focusing on dermatologic issues related to CGM and CSII in pediatric patients, finding that contact dermatitis was the most common complication reported.
- The findings highlight the need for better manufacturer transparency and further research to address how these skin complications may impact long-term T1D management in young patients.
Efficacy of Sound Touch Elastography in Assessing Subcutaneous Lipohypertrophy from Insulin Injections.
Diabetes Metab Syndr Obes
November 2024
Department of Ultrasound Medicine, Affiliated People's Hospital of Ningbo University, Ningbo, Zhejiang, 315040, People's Republic of China.
Objective: Lipohypertrophy (LH) is a localized complication of type 2 diabetes mellitus in patients on long-term insulin therapy. Sound touch elastography (STE) is a crucial tool in the quantitative real-time assessment of tissue hardness within specific target regions. This study aims to explore the efficacy of STE in evaluating the hardness of subcutaneous LH at insulin injection sites in individuals with type 2 diabetes mellitus and investigate the correlations between the hardness of LH lesions and various clinical indicators.
View Article and Find Full Text PDFOnce-weekly semaglutide in people with HIV-associated lipohypertrophy: a randomised, double-blind, placebo-controlled phase 2b single-centre clinical trial.
Lancet Diabetes Endocrinol
August 2024
Department of Medicine, Division of Infectious Diseases, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
Article Synopsis
- HIV-associated lipohypertrophy is a condition marked by excess abdominal fat in people living with HIV, leading to increased health risks, and current treatment options are insufficient.
- A clinical trial tested the effectiveness of semaglutide, a GLP-1 receptor agonist, in reducing this abnormal fat accumulation among HIV patients without diabetes.
- Results showed significant decreases in abdominal visceral fat and total body fat after 32 weeks of treatment with semaglutide compared to placebo, indicating its potential as an effective intervention for lipohypertrophy in this population.
Prevalence of skin problems caused by insulin pump therapy and associated factors in children with type 1 diabetes mellitus: A large cross-sectional survey in China.
Diabetes Res Clin Pract
June 2024
Department of Child Health Care, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou 310052, Zhejiang Province, PR China. Electronic address:
Article Synopsis
- A study was conducted to assess the prevalence of skin problems related to insulin pump use in children with type 1 diabetes in China, involving 461 participants from an online group.
- Results showed that about 66.8% of children experienced skin issues, including pigmentation changes, allergies, and infections, with significant factors identified being the caregiver's education level, existing skin allergies, and the specific brand of insulin pump used.
- The findings suggest that health education should incorporate these factors, alongside the typical focus areas, to improve care for children using insulin pumps.
Pen needle use patterns in an insured population with diabetes: U.S. retrospective claims analysis.
J Am Pharm Assoc (2003)
September 2024
Background: People with diabetes who inject insulin with pen devices may reuse the pen needles (PNs), a practice that can cause PN tip deformity, breakage, and contamination, and that is associated with lipohypertrophy and injection-related pain.
Objective: This retrospective study aimed to estimate the extent of PN reuse among people with diabetes in 2 insured populations in the United States.
Methods: Using claims data for Commercial Fully Insured (CFI) and Medicare Advantage (MA) populations from 1-Oct-2018 to 31-Dec-2022, we identified adults with type 1 or type 2 diabetes (T1D/T2D) who had ≥ 1 claim for PNs and ≥ 2 claims for insulin from 1-Jan-2019 to 31-Dec-2021, with continuous medical/pharmacy eligibility for 3 months before first claim and 1 year after (follow-up).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!